Bausch Health Companies Inc. (BHC)

19.53
NYSE
Prev Close 19.17
Day Low/High 19.23 / 19.64
52 Wk Low/High 11.15 / 31.97
Exchange NYSE
Shares Outstanding 355.15B
Market Cap 6.81B
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

2 Lackluster Names Insiders Are Buying

2 Lackluster Names Insiders Are Buying

Bausch Health and Greenbrier Cos. have seen large chunks of their shares bought recently by people close to the companies.

Reports to Watch for Wednesday Morning

As I mentioned earlier, I've got the LendingClub earnings report to deal with after today's market close, but here are several reports that are likely to drive tomorrow's market open:  Economic January PPI January Housing Starts & Building Permits  ...

Bausch Health Looks a Little Blurry Ahead of Earnings

Bausch Health Looks a Little Blurry Ahead of Earnings

Let's check out the charts of this Canada-based company.

The Week Ahead: Earnings Season Is Far From Over

The Week Ahead: Earnings Season Is Far From Over

Disney, Qualcomm and Square are among 75 key reports we are watching.

Bausch Health Is Struggling to Go Sideways - Risk of Being Long

Bausch Health Is Struggling to Go Sideways - Risk of Being Long

Let's review the charts and indicators of BHC.

Bausch Health: Long-Term Promise or Stalled at the Top of the Range?

Bausch Health: Long-Term Promise or Stalled at the Top of the Range?

Shares of BHC are up 41% for the year, but we need to be forward looking and check out the charts too.

Is Elon Musk Mortgaging Tesla Shares Against a Potential Margin Call?

Is Elon Musk Mortgaging Tesla Shares Against a Potential Margin Call?

Short-sellers are pointing to a big risk for Tesla investors and an opportunity for traders.

These 3 Biotech Stocks Are Moving Closer to Profitability

These 3 Biotech Stocks Are Moving Closer to Profitability

Here are updates on small biotech/biopharma names I have profiled before.

My Post-Earnings Assessment of 2 Biotech Stocks

My Post-Earnings Assessment of 2 Biotech Stocks

Let's look at a couple of companies we have covered on these pages before.

Rules of Biotech Investing Change, and So Must Biotech Investors

Rules of Biotech Investing Change, and So Must Biotech Investors

One big change over the last few years has been the struggle of small concerns to penetrate mass markets even with approved and superior drugs.

3 Small Biotechs to Watch as Earnings Season Winds Down

3 Small Biotechs to Watch as Earnings Season Winds Down

One already is up nicely on its results, while the other two should issue reports of interest in the next few days.

Bausch Health Is Likely to Dip Before Moving Higher Longer-Term

Bausch Health Is Likely to Dip Before Moving Higher Longer-Term

Traders look like they have taken a neutral to bearish stance ahead of earnings.

The Week Ahead: Housing, Fed Minutes and 13 Tell-Tale Earnings Reports to Watch

The Week Ahead: Housing, Fed Minutes and 13 Tell-Tale Earnings Reports to Watch

A shortened week still brings key economic numbers and earnings results.

Can Bausch Health Convince the Charts of its Comeback Story?

Can Bausch Health Convince the Charts of its Comeback Story?

Let's check and see.

My 2 Top Stock Picks for 2019

My 2 Top Stock Picks for 2019

It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.

Here Are 3 Small-Cap Names for Biotech Investors to Consider

Here Are 3 Small-Cap Names for Biotech Investors to Consider

We look at a slightly riskier part of the sector...that should be able to reach profitability with little to no additional funding needs.

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.

Bausch Health: A Company Can Change Its Name but Not Its Chart History

Bausch Health: A Company Can Change Its Name but Not Its Chart History

Shares of the former Valeant Pharmaceuticals have rallied the past 12 months, but can the strength continue?

Bausch Builds Big Sans Bill Ackman

Ackman Checks In to Hilton

Ackman Checks In to Hilton

Ackman's fund bought the hotelier's stock in 2016 and cashed out the following year for a gain of about 30%.

My Options Strategy for These 2 Biotech Stocks

My Options Strategy for These 2 Biotech Stocks

It's weeks like this that I'm glad I have some 'dry powder' to deploy.

Musk Charges Prompt Comparisons of Tesla With Valeant, Enron

Musk Charges Prompt Comparisons of Tesla With Valeant, Enron

Former Kase Capital managing partner says Tesla shares likely to spiral downward.

Buy High, Sell Low!

For the first time in a decade, corporate share buybacks are taking up the largest portion of capital expenditures: Memo to Self: Companies are notorious poor market timers in buying their own shares. I give you such examples as Bausch Health Cos.  ...

Buy Struggling Progenics and Dynavax Here

Buy Struggling Progenics and Dynavax Here

Both biotech stocks are at or near 52-week lows, but don't deserve to be.

Names to Watch Amid Biotech's Nascent Rally

Names to Watch Amid Biotech's Nascent Rally

Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.